Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03452189 · ClinicalTrials.gov registry record · Phase 2
The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT03452189 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 15 participants.
The verdict
NCT03452189, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if multiple doses of vancomycin over the course of 3 months will perturb the intestinal flora (microbiome) and result in reduced serum concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the study will permit investigators to assess the variability of serum uremic retention solute concentrations with and without antibiotic over a three-month period.
Interventions
- OTHER Placebo
- DRUG Vancomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2018-08-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03452189
The ClinicalTrials.gov registry entry for NCT03452189 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03452189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03452189 about?
NCT03452189 is a clinical study titled "The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome". The purpose of this study is to determine if multiple doses of vancomycin over the course of 3 months will perturb the intestinal flora (microbiome) and result in reduced serum concentration of the uremic toxin indoxyl sulfate and p-cresyl sulfate. The design of the study will permit investigators t...
What is the current status of trial NCT03452189?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2017-11-27. Estimated completion is 2018-08-18.
What interventions are being tested in trial NCT03452189?
The interventions under investigation include: Placebo (OTHER), Vancomycin (DRUG).
Who is sponsoring clinical trial NCT03452189?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.